LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Jasper Therapeutics, Inc. ("Jasper†or the "Company†) (NASDAQ: JSPR) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON JASPER THERAPEUTICS, INC. (JSPR), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happen. ...

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Jasper Therapeutics, Inc. ("Jasper†or the "Company†) (NASDAQ: JSPR) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN JASPER THERAPEUTICS, INC. (JSPR), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal. ...

LOS ANGELES--(BUSINESS WIRE)---- $JSPR--Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – JSPR. ...

NEW YORK , Sept. 22, 2025 /PRNewswire/ -- Why:Â Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusive (the "Class Period"). ...

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Jasper Therapeutics, Inc. ("Jasper†or the "Company†) (NASDAQ: JSPR) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON JASPER THERAPEUTICS, INC. (JSPR), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On July 7, 2025, Jasper released an update on its Phas. ...

Core Viewpoint - A class action lawsuit has been filed against Jasper Therapeutics, Inc. for allegedly misleading investors regarding the commercial prospects of its lead product candidate, Briquilimab, which has resulted in significant stock price decline [1][2][3]. Group 1: Allegations and Issues - The lawsuit claims that Jasper Therapeutics failed to disclose critical information about its manufacturing controls and procedures, which were necessary to ensure compliance with cGMP regulations [2]. - This lack of disclosure allegedly increased the risk of confounding results in ongoing studies, negatively impacting the regulatory and commercial prospects of the company's products, including Briquilimab [2]. - The failure to maintain proper controls also raised the likelihood of disruptive cost-reduction measures, leading to overstated business and financial prospects for the company [2]. Group 2: Stock Price Impact - Following the revelation of these issues on July 7, 2025, Jasper's stock price plummeted by $3.73 per share, representing a 55.1% decrease, closing at $3.04 per share [3]. Group 3: Class Action Participation - Shareholders of Jasper Therapeutics may be eligible to participate in the class action and can contact Robbins LLP if they wish to serve as lead plaintiffs [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4].

NEW YORK--(BUSINESS WIRE)---- $JSPR #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Jasper Therapeutics, Inc. ("Jasper†or the "Company†) (NASDAQ: JSPR) and reminds investors of the November 18, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgi ...

Core Viewpoint - A securities class action lawsuit has been filed against Jasper Therapeutics, Inc. for allegedly making false and misleading statements regarding its manufacturing processes and the prospects of its products, particularly briquilimab [1][2]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Northern District of California on behalf of individuals or entities that purchased Jasper securities between November 30, 2023, and July 3, 2025 [1]. - The complaint alleges that Jasper lacked necessary controls and procedures to ensure third-party manufacturers complied with cGMP regulations, which could negatively impact clinical trial results [2]. Group 2: Allegations Against the Company - The failure to ensure compliance with manufacturing regulations increased the risk of confounding study results, adversely affecting the regulatory and commercial prospects of Jasper's products [2]. - The allegations suggest that the company's business and financial prospects, as well as the clinical and commercial prospects of briquilimab, were overstated [2]. - As a result of these issues, the public statements made by the defendants were materially false and misleading throughout the relevant period [2]. Group 3: Investor Information - Investors who acquired shares of Jasper are encouraged to contact the law firm Gainey McKenna & Egleston before the lead plaintiff motion deadline on November 18, 2025 [3].

Core Points - A shareholder class action lawsuit has been filed against Jasper Therapeutics, Inc. alleging materially false and misleading statements regarding the company's business and compliance policies [1] - The lawsuit claims that Jasper lacked necessary controls to ensure third-party manufacturers complied with cGMP regulations, which could negatively impact clinical trial results and the commercial prospects of its product briquilimab [1] - The allegations suggest that Jasper's business and financial prospects, as well as briquilimab's clinical and commercial prospects, were overstated [1] Legal Context - Shareholders who purchased Jasper shares between November 30, 2023, and July 3, 2025, and experienced significant losses are encouraged to discuss their legal rights [2] - The deadline to request lead plaintiff status in the lawsuit is November 18, 2025 [3] - Holzer & Holzer, LLC is representing shareholders in this litigation and has a history of recovering significant amounts for investors affected by corporate misconduct [3]

Core Viewpoint - Investors in Jasper Therapeutics, Inc. have the opportunity to lead a securities fraud lawsuit against the company with the Schall Law Firm [1] Group 1 - The lawsuit is centered around allegations of securities fraud involving Jasper Therapeutics, Inc. [1] - The Schall Law Firm is actively seeking investors to participate in the lawsuit [1]